Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma

Sorafenib is a multiple kinase inhibitor which targets Raf kinases, VEGFR, and PDGFR and is approved for the treatment of hepatocellular carcinoma (HCC). Previously, we found that p-STAT3 is a major target of SC-43, a sorafenib derivative. In this study, we report that SC-43-induced apoptosis in cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ming-Hung, Chen, Li-Ju, Chen, Yen-Lin, Tsai, Ming-Shen, Shiau, Chung-Wai, Chao, Tzu-I, Liu, Chun-Yu, Kao, Jia-Horng, Chen, Kuen-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630313/
https://www.ncbi.nlm.nih.gov/pubmed/29029413
http://dx.doi.org/10.18632/oncotarget.17779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630313/
https://www.ncbi.nlm.nih.gov/pubmed/29029413
http://dx.doi.org/10.18632/oncotarget.17779

Ejemplares similares